Becker's Healthcare January 22, 2025
In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22.
Humira (adalimumab), a popular immunosuppressive medication, and its 22 biosimilars are largely absent from the formularies of Cigna’s Express Scripts, CVS Caremark and UnitedHealth Group’s Optum Rx.
Most FDA-approved biosimilars are not on the PBMs’ formularies, according to Drug Channels. They do include, however, a select few of biosimilars marketed by an affiliated company’s private-label business.
For example, a UnitedHealth Group segment runs Optum Rx and a new private-label business, Nuvaila. Optum Rx’s...
Today's Sponsors
Today's Sponsor